Go Pro
→ A $382 trillion migration and the position no one is talking about (From Awesomely) (Ad)tc pixel Free KROS Stock Alerts

Keros Therapeutics (KROS) Short Interest Ratio & Short Volume

Keros Therapeutics logo
$11.03 -0.20 (-1.78%)
As of 08/28/2026 04:00 PM Eastern
Compare

Keros Therapeutics Short Interest Overview

As of August 14, 2026, Keros Therapeutics (KROS) had a short interest of 1.15 million shares sold short, representing 6.63% of the public float. This marks a 16.57% increase in short interest since the prior report. The short interest ratio (days to cover) is 4.7, meaning it would take 4.7 days of the average trading volume of 223,647 shares to cover all short positions.

Current Short Interest
1,148,951 shares
Previous Short Interest
985,590 shares
Change Vs. Previous Month
16.57%
Dollar Volume Sold Short
$11.60 million
Short Interest Ratio
4.7 Days to Cover
Last Record Date
August 14, 2026
Outstanding Shares
19,830,000 shares
Short Percent of Float
6.63%
Today's Trading Volume
328,287 shares
Average Trading Volume
223,647 shares
Today's Volume Vs. Average
147%
Short Selling Keros Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Keros Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

KROS Short Interest Over Time

KROS Days to Cover Over Time

KROS Percentage of Float Shorted Over Time

Keros Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
8/14/20261,148,951 shares $11.60 million +16.6%6.6%4.73 $10.10
7/31/2026985,590 shares $9.92 million -6.9%5.7%5.92 $10.07
7/15/20261,058,882 shares $11.68 million +3.2%6.1%4.08 $11.03
6/30/20261,026,323 shares $10.98 million -27.1%6.5%2.54 $10.70
6/15/20261,407,890 shares $14.42 million -6.7%9.0%6.6 $10.24
5/29/20261,508,786 shares $16.97 million -11.5%9.9%4.54 $11.25
5/15/20261,704,362 shares $17.90 million +20.4%10.8%4.65 $10.50
4/30/20261,415,972 shares $15.75 million +1.2%9.3%5.36 $11.12
4/15/20261,399,759 shares $16.39 million -6.4%8.9%3.47 $11.71
3/31/20261,494,814 shares $16.50 million -24.9%8.6%2.63 $11.04
3/13/20261,989,399 shares $21.92 million -2.1%13.1%3.52 $11.02
2/27/20262,031,197 shares $28.82 million -14.8%8.6%6.6 $14.19
2/13/20262,383,895 shares $39.52 million +4.7%15.6%8.82 $16.58
1/30/20262,277,105 shares $40.78 million -2.9%9.7%8.84 $17.91
1/15/20262,345,217 shares $45.17 million -5.6%10.0%5.25 $19.26
12/31/20252,484,362 shares $50.58 million -7.7%10.6%4.58 $20.36
12/15/20252,692,419 shares $57.16 million -16.6%11.5%3.04 $21.23
11/28/20253,228,958 shares $56.51 million -52.4%13.7%2.4 $17.50
11/14/20256,781,420 shares $117.05 million +15.7%28.9%5.39 $17.26
10/31/20255,862,479 shares $89.23 million +53.6%25.0%5.41 $15.22
10/15/20253,820,000 shares $55.35 million -1.3%16.3%6.5 $14.49
9/30/20253,870,000 shares $61.22 million -16.2%N/A8.9 $15.82
9/15/20254,620,000 shares $71.84 million +2.7%N/A10.5 $15.55
8/31/20254,500,000 shares $68.45 million -6.8%14.0%9 $15.21
8/15/20254,830,000 shares $69.94 million -0.2%N/A9.1 $14.48
7/31/20254,840,000 shares $69.31 million -4.2%15.0%8.5 $14.32
7/15/20255,050,000 shares $71.96 million -2.1%N/A7.6 $14.25
6/30/20255,160,000 shares $68.89 million +9.8%16.0%5.8 $13.35
6/15/20254,700,000 shares $63.73 million -11.5%14.6%5 $13.56
5/31/20255,310,000 shares $75.77 million -8.0%17.0%5.4 $14.27
5/15/20255,770,000 shares $80.95 million +9.5%18.5%5.5 $14.03
4/30/20255,270,000 shares $76.10 million +19.5%N/A4.8 $14.44
4/15/20254,410,000 shares $57.73 million +8.9%14.1%3.9 $13.09
3/31/20254,050,000 shares $41.27 million +0.8%13.0%3 $10.19
3/15/20254,020,000 shares $46.55 million -3.8%12.9%3 $11.58
2/28/20254,180,000 shares $46.31 million +1.2%13.4%2.5 $11.08
2/15/20254,130,000 shares $42.62 million -3.1%13.2%2.6 $10.32
1/31/20254,260,000 shares $48.56 million +6.0%N/A2.8 $11.40
1/15/20254,020,000 shares $41.89 million -6.7%N/A3 $10.42
12/31/20244,310,000 shares $68.23 million +42.2%N/A4.8 $15.83
Bezos… DOOMED (Ad)

A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.tc pixel

Watch James Altucher's free video breakdown before the September 25 deadline.
12/15/20243,030,000 shares $57.05 million +37.7%N/A3.8 $18.83
11/30/20242,200,000 shares $127.03 million -0.9%N/A5.7 $57.74
11/15/20242,220,000 shares $125.70 million -7.9%N/A6 $56.62
10/31/20242,410,000 shares $139.88 million -11.4%N/A6.9 $58.04
10/15/20242,720,000 shares $164.26 million -9.9%N/A8.1 $60.39
9/30/20243,020,000 shares $175.37 million -13.7%N/A8.7 $58.07
9/15/20243,500,000 shares $199.43 million +2.6%N/A9.7 $56.98
8/31/20243,410,000 shares $154.64 million -2.3%N/A9.2 $45.35
8/15/20243,490,000 shares $160.68 million +10.1%N/A9.7 $46.04
7/31/20243,170,000 shares $159.01 million +10.5%N/A9.2 $50.16
7/15/20242,870,000 shares $146.46 million +12.6%N/A8.4 $51.03
6/30/20242,550,000 shares $116.54 million -2.3%N/A7.8 $45.70
6/15/20242,610,000 shares $128.83 million +11.1%N/A8.4 $49.36
5/31/20242,350,000 shares $110.14 million -3.3%N/A7.6 $46.87
5/15/20242,430,000 shares $132.19 million +6.1%N/A7.3 $54.40
4/30/20242,290,000 shares $129.13 million +1.3%N/A6.6 $56.39
4/15/20242,260,000 shares $130.36 million +7.6%N/A6.1 $57.68
3/31/20242,100,000 shares $139.02 million +9.4%N/A5.1 $66.20
3/15/20241,920,000 shares $129.31 million +6.1%N/A4.3 $67.35
2/29/20241,810,000 shares $122.18 million +1.7%N/A3.8 $67.50
2/15/20241,780,000 shares $104.79 million +0.6%N/A4 $58.87
1/31/20241,770,000 shares $97.99 million +22.1%N/A4 $55.36
1/15/20241,450,000 shares $75.63 million +5.8%N/A3.6 $52.16
12/31/20231,370,000 shares $54.47 million -6.2%N/A3.8 $39.76
12/15/20231,460,000 shares $47.48 million +1.4%6.8%4.7 $32.52
11/30/20231,440,000 shares $43.69 million +18.0%6.8%5.3 $30.34
11/15/20231,220,000 shares $38.87 million -5.4%5.7%5.3 $31.86
10/31/20231,290,000 shares $36.82 million +1.6%6.1%6 $28.54
10/15/20231,270,000 shares $35.70 million -3.8%6.0%6.4 $28.11
9/30/20231,320,000 shares $42.08 million +11.9%6.3%7.1 $31.88
9/15/20231,180,000 shares $42.90 million +3.5%5.6%6.8 $36.36
8/31/20231,140,000 shares $40.03 million +0.9%5.4%5.3 $35.11
8/15/20231,130,000 shares $39.28 million +9.7%5.4%5.1 $34.76
7/31/20231,030,000 shares $43.14 million +5.8%4.9%4.6 $41.88
7/15/2023973,400 shares $39.57 million +11.1%4.7%4.6 $40.65
6/30/2023876,100 shares $35.20 million +0.1%4.2%4 $40.18
6/15/2023875,100 shares $33.98 million +6.5%4.2%3.9 $38.83
5/31/2023821,900 shares $39.34 million +19.7%4.0%4.1 $47.86
5/15/2023686,900 shares $32.25 million +12.0%3.3%3.4 $46.95
4/30/2023613,300 shares $27.20 million -0.5%3.0%3 $44.36
4/15/2023616,600 shares $23.92 million -14.3%3.1%2.8 $38.79
3/31/2023719,700 shares $30.73 million +2.2%3.6%3.2 $42.70
3/15/2023704,500 shares $30.67 million +19.3%3.6%3.2 $43.54
2/28/2023590,600 shares $31.43 million -3.3%3.0%2.7 $53.22
2/15/2023610,900 shares $34.66 million -4.8%3.2%3.3 $56.74
1/31/2023641,900 shares $37.60 million +7.4%3.4%3.3 $58.57
1/15/2023597,900 shares $29.39 million +4.1%3.2%3.1 $49.16
12/30/2022574,400 shares $27.58 million -0.2%3.1%2.6 $48.02
12/15/2022575,600 shares $28.60 million -3.3%3.1%2.6 $49.68
11/30/2022595,100 shares $29.66 million -16.2%3.3%2.6 $49.84
The retirement stock I'd buy before Nvidia today (Ad)

In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.tc pixel

Get Marc Chaikin's free presentation on this overlooked AI stock now
11/15/2022709,900 shares $31.78 million -1.8%4.0%3.2 $44.76
10/31/2022723,100 shares $36.40 million -4.1%4.1%3.3 $50.34
10/15/2022754,100 shares $33.13 million +12.8%4.6%3.4 $43.93
9/30/2022668,300 shares $25.14 million -4.6%4.0%3.2 $37.62
9/15/2022700,600 shares $27.81 million +3.2%4.2%3.4 $39.70
8/31/2022678,900 shares $24.01 million -12.5%4.3%3.1 $35.37
8/15/2022775,900 shares $31.13 million -23.9%4.9%3.3 $40.12
7/31/20221,020,000 shares $32.72 million -22.7%6.9%4.1 $32.08
7/15/20221,320,000 shares $40.35 million -4.4%8.9%5.7 $30.57
6/30/20221,380,000 shares $38.13 million +35.3%9.3%6.4 $27.63
6/15/20221,020,000 shares $28.82 million +10.2%6.9%5 $28.25
5/31/2022925,300 shares $31.28 million -6.6%6.3%5.4 $33.80
5/15/2022991,000 shares $43.59 million +12.7%6.7%6.6 $43.99
4/30/2022879,500 shares $46.62 million +4.1%6.0%7.2 $53.01
4/15/2022844,800 shares $54.60 million -11.9%5.7%6.7 $64.63
3/31/2022958,800 shares $52.14 million -15.2%6.7%7.7 $54.38
3/15/20221,130,000 shares $57.46 million No Change7.9%8.8 $50.85
2/28/20221,130,000 shares $60.68 million +7.6%8.1%8 $53.70
2/15/20221,050,000 shares $58.01 million +13.9%7.5%7.1 $55.25
1/31/2022921,600 shares $42.73 million +14.3%6.6%5.8 $46.37
1/15/2022806,500 shares $41.76 million -1.2%5.8%5 $51.78
12/31/2021816,300 shares $47.76 million -11.9%5.8%5.3 $58.51
12/15/2021926,300 shares $48.40 million +13.8%6.6%4.4 $52.25
11/30/2021813,800 shares $45.40 million +3.3%5.9%4.1 $55.79
11/15/2021788,200 shares $48.51 million -22.0%5.7%4.2 $61.54
10/29/20211,010,000 shares $42.14 million +1.0%7.4%5.7 $41.72
10/15/20211,000,000 shares $38.99 million -2.9%7.4%6.2 $38.99
9/30/20211,030,000 shares $40.75 million +20.5%7.7%6.2 $39.56
9/15/2021855,000 shares $26.67 million -4.1%6.4%7.2 $31.19
8/31/2021891,300 shares $29.98 million -10.5%6.7%7.4 $33.64

KROS Short Interest - Frequently Asked Questions

Short interest is the volume of Keros Therapeutics shares that have been sold short but have not yet been closed out or covered. As of August 14th, traders have sold 1,148,951 shares of KROS short. 6.63% of Keros Therapeutics' shares are currently sold short. Learn More on Keros Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KROS shares currently have a short interest ratio of 4.7. Learn More on Keros Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.63% of Keros Therapeutics' floating shares are currently sold short.

Keros Therapeutics saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,148,951 shares, an increase of 16.6% from the previous total of 985,590 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

6.63% of Keros Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Keros Therapeutics: Aclaris Therapeutics, Inc. (11.05%), Rigel Pharmaceuticals, Inc. (19.34%), 4D Molecular Therapeutics, Inc. (24.15%), Sensei Biotherapeutics, Inc. (3.44%), Pharming Group N.V. Sponsored ADR (0.10%), Nuvectis Pharma, Inc. (7.89%), Silence Therapeutics PLC Sponsored ADR (4.17%), Aura Biosciences, Inc. (6.05%), Shattuck Labs, Inc. (6.56%), Neurogene Inc. (17.19%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($71.57 billion), Invesco QQQ ($46.97 billion), iShares Russell 2000 ETF ($24.02 billion), Nebius Group N.V. ($15.37 billion), Sandisk Corporation ($12.60 billion), SPDR S&P Biotech ETF ($12.14 billion), Western Digital Corporation ($10.32 billion), iShares 20+ Year Treasury Bond ETF ($8.38 billion), VanEck Semiconductor ETF ($7.62 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($7.07 billion). View all of the most shorted stocks.

Short selling KROS is an investing strategy that aims to generate trading profit from Keros Therapeutics as its price is falling. KROS shares are trading down $0.20 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Keros Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KROS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KROS, twice per month. The most recent reporting period available is August, 14 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like KROS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:KROS is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/25/2026. FINRA publishes updated short interest twice a month.
From Our Partners
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Musk just exposed the crack in his empire
SpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...
The Oxford Club | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
He called Apple then saw 12,000%+ gains. Now he's pointing at THIS.
In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...
Eagle Publishing | Sponsoredtc pixel